Antares Pharma (NASDAQ:ATRS) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a note issued to investors on Friday.

Several other analysts also recently issued reports on the company. Piper Jaffray Companies reiterated a “buy” rating and set a $4.00 price target on shares of Antares Pharma in a research note on Friday, August 17th. HC Wainwright set a $5.00 price objective on Antares Pharma and gave the stock a “buy” rating in a research report on Friday, August 17th. Finally, ValuEngine raised Antares Pharma from a “hold” rating to a “buy” rating in a research report on Wednesday, August 8th.

ATRS opened at $3.21 on Friday. The stock has a market cap of $516.39 million, a PE ratio of -29.18 and a beta of 0.34. Antares Pharma has a 52-week low of $1.58 and a 52-week high of $4.09. The company has a quick ratio of 1.89, a current ratio of 2.33 and a debt-to-equity ratio of 1.01.

Antares Pharma (NASDAQ:ATRS) last released its quarterly earnings results on Tuesday, August 7th. The specialty pharmaceutical company reported ($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.01). The company had revenue of $14.16 million for the quarter, compared to the consensus estimate of $13.70 million. Antares Pharma had a negative return on equity of 64.96% and a negative net margin of 35.53%. equities research analysts forecast that Antares Pharma will post -0.1 earnings per share for the current year.

In related news, Director Jacques Gonella sold 49,507 shares of the business’s stock in a transaction dated Monday, August 13th. The stock was sold at an average price of $3.09, for a total transaction of $152,976.63. Following the completion of the transaction, the director now owns 9,985,848 shares of the company’s stock, valued at approximately $30,856,270.32. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert F. Apple sold 43,000 shares of the business’s stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $3.75, for a total value of $161,250.00. Following the transaction, the chief executive officer now directly owns 1,573,562 shares of the company’s stock, valued at approximately $5,900,857.50. The disclosure for this sale can be found here. Insiders have sold a total of 343,000 shares of company stock valued at $1,088,250 in the last three months. 12.20% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. Metropolitan Life Insurance Co. NY raised its holdings in Antares Pharma by 127.0% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 51,612 shares of the specialty pharmaceutical company’s stock valued at $133,000 after acquiring an additional 28,875 shares in the last quarter. United Services Automobile Association raised its holdings in Antares Pharma by 1,453.0% in the 2nd quarter. United Services Automobile Association now owns 405,261 shares of the specialty pharmaceutical company’s stock valued at $21,147,000 after acquiring an additional 379,166 shares in the last quarter. JW Asset Management LLC raised its holdings in Antares Pharma by 2.8% in the 2nd quarter. JW Asset Management LLC now owns 1,820,524 shares of the specialty pharmaceutical company’s stock valued at $4,697,000 after acquiring an additional 50,000 shares in the last quarter. FMR LLC raised its holdings in Antares Pharma by 38.8% in the 2nd quarter. FMR LLC now owns 3,640,800 shares of the specialty pharmaceutical company’s stock valued at $9,393,000 after acquiring an additional 1,018,300 shares in the last quarter. Finally, BlackRock Inc. raised its holdings in Antares Pharma by 7.3% in the 2nd quarter. BlackRock Inc. now owns 9,805,325 shares of the specialty pharmaceutical company’s stock valued at $25,298,000 after acquiring an additional 664,681 shares in the last quarter. 38.93% of the stock is owned by hedge funds and other institutional investors.

Antares Pharma Company Profile

Antares Pharma, Inc, a specialty pharmaceutical company, focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; and Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults.

See Also: Short Selling Stocks and Day Traders

Receive News & Ratings for Antares Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Antares Pharma and related companies with MarketBeat.com's FREE daily email newsletter.